Description: Innovation1 Biotech Inc. operates as a small molecule drug discovery company. Its portfolio includes five proprietary fully synthetic preclinical prodrugs addressing independent clinical indications comprising a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression; a novel cannabinoid for treatment of addiction; and three additional cannabinoid prodrugs addressing clinical indications of refractory epilepsy, burn wounds, and uveitis. The company was formerly known as Gridiron BioNutrients, Inc. and changed its name to Innovation1 Biotech Inc. in March 2022. The company was founded in 2014 and is based in New York, New York.
Home Page: www.innovation1bio.com
40 Wall Street
New York,
NY
10005
United States
Phone:
646-380-1923
Officers
| Name | Title |
|---|---|
| Mr. Jeffrey Jay Kraws | CEO & Director |
| Tammy Phillips | Managing Director |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0171 |
| Price-to-Book MRQ: | 0.0472 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 1 |